MG
SRPT icon

Michael Gelband’s Sarepta Therapeutics SRPT Stock Holding History

Michael Gelband’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-63,210
Closed -$1.22M – 2044
2025
Q3 		$1.22M Buy
+63,210
New +$1.13M 0.01% 890
2025
Q2 		– Sell
-145,919
Closed -$9.31M – 1945
2025
Q1 		$9.31M Buy
+145,919
New +$15.4M 0.09% 226
2024
Q4 		– Sell
-43,106
Closed -$5.38M – 2021
2024
Q3 		$5.38M Sell
43,106
-74,109
-63% -$10.2M 0.03% 398
2024
Q2 		$18.5M Buy
117,215
+12,062
+11% +$1.55M 0.13% 144
2024
Q1 		$13.6M Buy
105,153
+97,646
+1,301% +$12M 0.1% 158
2023
Q4 		$724K Sell
7,507
-79,906
-91% -$7.67M ﹤0.01% 928
2023
Q3 		$10.6M Buy
+87,413
New +$9.88M 0.1% 209
2023
Q2 		– Sell
-4,053
Closed -$559K – 2225
2023
Q1 		$559K Sell
4,053
-152,972
-97% -$19.8M ﹤0.01% 1307
2022
Q4 		$20.3M Buy
157,025
+129,515
+471% +$15M 0.3% 67
2022
Q3 		$3.04M Sell
27,510
-78,177
-74% -$7.88M 0.04% 589
2022
Q2 		$7.92M Buy
105,687
+91,319
+636% +$6.72M 0.1% 250
2022
Q1 		$1.12M Sell
14,368
-1,196
-8% -$91.6K 0.01% 1077
2021
Q4 		$1.4M Buy
+15,564
New +$1.33M 0.01% 906
2021
Q3 		– Sell
-14,862
Closed -$1.16M – 2604
2021
Q2 		$1.16M Sell
14,862
-21,626
-59% -$1.64M 0.01% 933
2021
Q1 		$2.72M Buy
+36,488
New +$3.37M 0.04% 456
2020
Q2 		– Sell
-2,409
Closed -$236K – 2014
2020
Q1 		$236K Sell
2,409
-4,067
-63% -$465K 0.01% 720
2019
Q4 		$836K Buy
+6,476
New +$654K 0.02% 628

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Michael Gelband's SRPT Position: Q4 2025 in Review

Michael Gelband sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 63,210 shares — an estimated $1.22M sold.

Michael Gelband first reported a position in SRPT in Q4 2019 and held it in 17 quarters. The position peaked at $20.3M in Q4 2022. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Michael Gelband reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Michael Gelband sold 63,210 Sarepta Therapeutics shares in Q4 2025, an estimated $1.22M.
  • Michael Gelband first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 17 quarters.
  • Michael Gelband's Sarepta Therapeutics position peaked at $20.3M in Q4 2022.
  • 346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.